Key result
Celecoxib significantly improved functional status and overall health-related quality of life compared with placebo, and was comparable to naproxen in patients with rheumatoid arthritis.
Why the study?
Does celecoxib improve functional status and health-related quality of life in patients with active rheumatoid arthritis compared to placebo or naproxen?
Population
1,149 patients with diagnosed and active rheumatoid arthritis (RA)
Comparison
Celecoxib 100 mg, 200 mg, or 400 mg twice a day… vs Placebo or naproxen 500 mg twice a day
Design
RCT, randomized, parallel group, double-blind
Follow-up
12 weeks
Authors
Loading...
Enhances HRQOL and function in active RA; confirms 200 mg celecoxib superiority over placebo and naproxen in RCT.
RCT (n=1,149)
Double-blind
parallel group
Yes
Does celecoxib improve functional status and health-related quality of life in patients with active rheumatoid arthritis compared to placebo or naproxen?
Celecoxib effectively improves functional status and quality of life in patients with active rheumatoid arthritis, performing better than placebo and comparably to or better than naproxen.
Zhao et al. (2000) conducted an RCT in rheumatoid arthritis (n=1,149). Celecoxib vs. Placebo and naproxen (500 mg twice a day) was evaluated on Functional status (HAQ disability index) and general health-related quality of life (SF-36). Celecoxib significantly improved functional status and overall health-related quality of life compared with placebo, and was comparable to naproxen in patients with rheumatoid arthritis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: